Skip to main content

Table 1 Baseline characteristics and demographics of Italian patients enrolled in the PATRO Children study up to August 2015

From: Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study

Characteristic N = 186
Gender(%)  
 Male 107 (57.5)
 Female 79 (42.5)
Chronological age, years 10.2 ± 3.3
HSDS ± SD −2.29 ± 0.86 (Nmiss = 30)
Height velocity, cm/year ± SD 3.9 ± 2.1 (Nmiss = 91)
BMI, kg/m2 ± SD 17.2 ± 3.6 (Nmiss = 35)
Diagnosis at presentation, n (%)  
 GHD 156 (84.0)
 SGA 12 (6.5)
 TS 3 (1.6)
 PWS 7 (3.8)
 CRI 1 (0.5)
 Other 7 (3.8)
Previous treatment status, n (%)  
 Hormone naïve 167 (89.8)
 Pre-treated 19 (10.2)
Omnitrope® dosing at baseline, mg/kg/day 0.032 ± 0.008
Duration of Omnitrope® treatment, months 28.3 ± 19.1
  1. All values are presented as mean ± standard deviation unless otherwise stated
  2. BMI body mass index, CRI chronic renal insufficiency, GHD growth hormone deficiency, HSDS Height Standard Deviation Scores, N miss number of patients with data missing, PWS Prader-Willi syndrome, SD standard deviation, SGA small for gestational age, TS Turner syndrome